Manuscripts

2019

Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. Journal of Rheumatology, 2019, 171034, Epub ahead of print.
Also Poster 2016 ACR.

2018

A Ogdie, JL Palmer, J Greenberg, JR Curtis, LR Harrold, DH Solomon, A Kavanaugh, JM Kremer, P Mease.
Predictors of achieving remission among patients with psoriatic arthritis initiating a TNF inhibitor.
Conclusion: Few PsA patients in a US-based registry achieved remission by CDAI criteria. Female sex, obesity, comorbidities, and socioeconomic status influence achievement of remission on a TNFi.
In Press, Journal of Rheumatology.

Curtis JR, Greenberg JD, Harrold LR, Kremer JM, Palmer JL. Influence of obesity, age and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2018 47:472-477. Also Poster 2016 ACR.

JR Curtis, JD Greenberg, LR Harrold, JM Kremer, JL Palmer.
Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis.
Conclusion: In this real-world analysis, the MBDA score was associated with RA disease activity, obesity and age, and was negligibly affected by common comorbidities. Almost one-third of patients with normal CRP had high MBDA scores. An adjustment to the MBDA score to account for body mass index and age is proposed.
Published, Seminars in Arthritis and Rheumatism, 2018 Feb;47(4):472-477. PMID: 28947312

2017

Cappelli LC, Palmer JL, Kremer J, Bingham CO. Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2017, 47:165-169. Also Poster 2016 ACR.

2016

Anandarajah AP, El-Taha M, Peng C. The Relationship between Focal and Generalized Bone Loss in Rheumatoid Arthritis. Curr Rheumatol Rev. 2016 Sep 8. [Epub ahead of print].

Abstracts

2019 (Submitted for Publication)

Ocon T, Albany Medical College. Influence of corticosteroid cumulative dose on cardiovascular events in patient with rheumatoid arthritis. In preparation for manuscript submission.

Baker J. U of Pennsylvania. Influence of disease activity on cardiovascular disease in patient with rheumatoid arthritis. In preparation for manuscript submission.

Curtis JR, Palmer L, Reed G, Greenberg JD, Pappas D, Harrold L, Kremer J. Real-world outcomes associated with triple therapy vs TNFi combo therapy: Results from the Corrona registry. Poster 2018 ACR, being prepared for manuscript submission.

2018

JM Kremer, JL Palmer, GW Reed, D Pappas, LR Harrold, JD Greenberg, JR Curtis
Clinical and Sociodemographic Characteristics of Patients with Rheumatoid Arthritis (RA) Starting Triple Therapy and a Combination of a TNF Inhibitor and Methotrexate from a Large US Registry
Conclusion: Utilization of Triple was not common over a period of 16 years covered by the registry. Pts started on triple were older, had less severe RA and a higher comorbidity burden. These differences are likely to impact response to treatment as it appears that rheumatologists channeled pts with more severe RA to TNFi + MTX, while pts with a h/o comorbidities were more likely to receive Triple.
Poster Presented at ACR 2018.

JR Curtis, L Palmer, G Reed, JD Greenberg, D Pappas, L Harrold, J Kremer
Real-World outcomes associated with Triple Therapy vs. TNFi Combo Therapy: Results from the Corrona Registry
Conclusion: Based on real world evidence from a large U.S. RA registry, use of Triple is uncommon, and outcomes associated with Triple are less favorable compared to combination therapy with TNFi+MTX.
Poster Presented at ACR 2018.

Kremer JM, Palmer JL, Reed GW, Pappas D, Harrold LR, Greenberg JD, Curtis JR. Clinical and sociodemographic characteristics of patient with rheumatoid arthritis starting triple therapy and a combination of a TNF inhibitor and methotrexate from a large US registry. Poster 2018 ACR, being prepared for manuscript submission.

2017

Birju D Bhatt, JL Palmer, JR Curtis, JM Kremer.
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis in patients with PsA, there was a significant positive relationship between blood pressure and both psoriasis BSA and joint disease activity, measured by CDAI. We also conclude that clinically, the initiation of TNFi did decrease blood pressure, but the decrease was not significant. We believe that this is the first study to look at relationships between the initiation of TNFi treatment and blood pressure in PsA patients.
Poster presented at ACR 2017.

Bhatt D, Albany Medical College, Palmer JR, Curtis JR, Kremer JM. Changes in blood pressure with TNF inhibitors in patients with psoriatic arthritis. Poster 2017 ACR, in preparation for manuscript submission.

2016

JR Curtis, L Harrold, J Kremer, JL Palmer
Higher Multi Biomarker Disease Activity Scores Foreshadow Greater Longitudinal Improvement in RA Disease Activity
Among RA patients with high baseline disease activity (measured by CDAI) and who started a new medication for RA, patients with high MBDA scores (>44) were associated with significantly greater improvement in the CDAI over time compared to those with high CDAI and lower MBDA scores. The MBDA test may be useful to select patients who subsequently have a better response to treatment and thus provide utility even beyond clinical assessments of RA disease activity such as CDAI.
Poster presented at ACR 2016.

A Ogdie, JL Palmer, JD Greenberg, LR Harrold, DH Solomon, A Kavanaugh, J Kremer, JR Curtis, PJ Mease.
Predictors of response to TNF alpha inhibitors among patients with psoriatic arthritis.
Female sex, obesity, higher CDAI at baseline, hypertension and previous biologic use were predictors of not achieving remission whereas college education (or higher) was associated with remission. Similar predictors were identified for achieving low disease activity.
Poster presented at ACR 2016.

LC Cappelli, JL Palmer, CO Bingham
Clinical Responses to Tocilizumab Analyzed by Serologic Status in Rheumatoid Arthritis
Patients treated with TCZ had improvement in a variety of disease activity measures at initial follow up, regardless of serologic status. This remained true when adjusted for baseline disease activity level and disease duration and regardless of definition used for serologic status (RF vs CCP vs either positive). The results suggest that TCZ may be equally useful in seronegative and seropositive patients, unlike some other biologic DMARDs.
Poster presented at ACR 2016.

LR Harrold, JL Palmer, JR Curtis, D Pappas, JD Greenberg, JM Kremer
Trends over Time in Achievement of Low Disease Activity Among Biologic Initiators with Rheumatoid Arthritis. Using the U.S. Corrona registry, the proportion of RA patients achieving LDA when initiating a biologic in moderate or high disease activity has increased over time.
Poster presented at EULAR 2016 (updated from ACR2015)

2015

LR Harrold, JL Palmer, JR Curtis, JD Greenberg, JM Kremer
Trends over Time in Achievement of Low Disease Activity Among Biologic Initiators with Rheumatoid Arthritis. Using the U.S. Corrona registry, the proportion of RA patients achieving LDA when initiating a biologic in moderate or high disease activity has increased over time.
Poster presented at ACR 2015

Harrold LR, Palmer JL, Curtis JR, Greenberg JD, Kremer JM. Trends over time in achievement of low disease activity among biologic initiators with rheumatoid arthritis. Poster ACR 2015.